- 01Count the boats, not the cargo
apoB counts the atherogenic particles that can lodge in an artery wall; LDL-C only estimates the cholesterol inside them. Two people can share the same LDL-C while one carries far more particles, and that person carries more risk.
- 02Discordance is where apoB earns its keep
When apoB and LDL-C disagree, common with high triglycerides and insulin resistance where particles are numerous but cholesterol-poor, apoB predicts heart attack risk more accurately than LDL-C or non-HDL-C.
- 03apoB includes Lp(a), but does not isolate it
apoB counts Lp(a) particles along with LDL, so a normal apoB does not rule out high, inherited Lp(a). The two tests answer different questions.
Your LDL cholesterol tells you how much cholesterol is riding inside your low-density lipoprotein particles. Apolipoprotein B (apoB) tells you how many of those particles you have, because every atherogenic particle carries exactly one apoB molecule. That distinction matters, because it is the number of particles hitting your artery walls, not the cholesterol they carry, that drives atherosclerosis 16.
What apoB measures
"Atherogenic" particles are the ones that can push into an artery wall and start a plaque: LDL, plus VLDL, IDL, and Lp(a). Each of these carries one, and only one, apolipoprotein B-100 molecule on its surface, the structural scaffold that holds the particle together. So a plasma apoB result is a direct count of every atherogenic particle in a sample of your blood, no matter how much or how little cholesterol each one happens to be carrying 1.
Because each atherogenic particle carries one molecule of apolipoprotein B, plasma apoB is a direct measure of the number of atherogenic particles.After Sniderman AD et al., JAMA Cardiology, 2019
This is the base fact the rest of the page builds on. If you want the mechanics of how a standard lipid panel is drawn and reported, we defer that to how to read your lipid panel rather than repeat it here.
What a high apoB means
A high apoB means you carry a lot of atherogenic particles, and more particles means more chances for one to lodge in an artery wall over the years. A single lab reference range flags apoB as "high" only past a risk cutoff, but the level considered optimal for preventing heart disease is lower. Both numbers are useful, and they answer different questions.
| apoB tier | Approx. level (mg/dL) | What it signals |
|---|---|---|
| Preventive goal (very high risk) | under ~65 | An ESC/EAS goal for very high risk, such as established cardiovascular disease 4 |
| Preventive goal (high risk) | under ~80 | An ESC/EAS goal used at high cardiovascular risk, not an average-risk target 4 |
| A common mid-range | mid-range | Interpretation depends on your overall risk, not the number alone |
| Risk-enhancing | 130 or above | The 2018 AHA/ACC guideline treats apoB >=130 mg/dL as a risk-enhancing factor supporting more intensive prevention 3 |
apoB vs LDL-C: count the boats, not the cargo
Picture your particles as a fleet of boats and the cholesterol as the cargo inside each hull. LDL-C weighs the total cargo, while apoB counts the boats. Most of the time the two move together, so either number tells a similar story. The gap opens when your boats are riding light.
When apoB and LDL-C point in different directions, that gap is called discordance. It shows up most in people with high triglycerides or insulin resistance, whose particles are numerous but cholesterol-poor, many small boats each carrying little cargo. LDL-C, which mostly reflects cargo, can look calm while the particle count is high. And because a standard panel usually calculates LDL-C from an equation that loses accuracy when triglycerides are high, the calm reading can be an underestimate on top of that.
When apoB and LDL-C disagree, the particle count wins. In an analysis of people with and without existing atherosclerosis, apoB predicted the risk of myocardial infarction more accurately than LDL-C or non-HDL-C 2. If you are holding both numbers off your own panel, the tool below shows where they sit relative to each other.
Do your apoB and LDL agree?
Enter both numbers to see whether your particle count and your cholesterol tell the same story. Nothing leaves your browser.

Where apoB fits with the rest of your panel
apoB is not a replacement for your lipid panel; it is a truer particle count layered on top of it. Here is how it lines up against the other numbers a report might show, and what each one is best at.
| Marker | What it measures | When it wins |
|---|---|---|
| LDL-C | Cholesterol inside LDL particles (usually calculated) | Cheap, universal, fine when it agrees with apoB 4 |
| non-HDL-C | Cholesterol in all atherogenic particles (total minus HDL) | A no-extra-cost upgrade over LDL-C when triglycerides are high 4 |
| apoB | Count of all atherogenic particles | When apoB and LDL-C disagree, or in diabetes, obesity, high triglycerides, very low LDL 2 4 |
| Lp(a) | One inherited, lifelong particle type | Once in a lifetime, to catch a genetic risk the others hide 5 |
non-HDL cholesterol is the closest free stand-in for apoB, because it captures the cholesterol in every atherogenic particle rather than LDL alone. If your report lists a total and an HDL, you can read the non-HDL number now.
Your non-HDL cholesterol
The closest stand-in for apoB you can get from a standard panel. Nothing leaves your browser.

apoB vs Lp(a): what is the difference?
apoB and Lp(a) measure different things. apoB counts particles you can move: diet, weight, activity, and the medications a clinician might use all change how many atherogenic particles you carry. Lp(a) is one specific particle type that you inherit and keep for life, and it barely responds to those same levers.
Lp(a) is set by your genes and barely moves with diet, exercise, or statins. You inherit your number and keep it for life.
Your apoB count includes your Lp(a) particles, but it does not separate them out. So a normal apoB does not rule out high Lp(a), and someone with high inherited Lp(a) can still have a reassuring apoB. They answer different questions, which is why the Lp(a) guideline recommends measuring it at least once in a lifetime on its own 5. If your goal is to understand the numbers your standard panel hides, apoB and Lp(a) are two separate pieces of that picture, both sitting under high cholesterol as the parent.
How apoB is tested
- 1Ask for it by nameapoB is usually a separate order from a basic lipid panel. You can ask a clinician to add apolipoprotein B to your next blood draw.
- 2Fasting is often not requiredUnlike calculated LDL-C, apoB is measured directly and is less affected by a recent meal, so many labs do not require fasting. Follow the instructions your lab gives you.
- 3It is a standard, low-cost blood testapoB is a widely available assay, not a specialty send-out, and typically costs far less than advanced particle-number testing. Coverage varies by plan and reason for testing.
- 4Retest around a change, not constantlyapoB is most useful for a baseline read and to see whether a change in habits or treatment moved your particle count. Your clinician sets the cadence.
What generally moves apoB
Because apoB tracks the number of atherogenic particles, anything that lowers LDL particle number tends to lower apoB. In broad terms that means reducing saturated fat, losing excess weight, staying active, and addressing the insulin resistance and high triglycerides that create the many-small-particle pattern in the first place. The drug classes clinicians use to lower LDL, starting with statins and adding ezetimibe or PCSK9-targeted agents when goals are not met, lower apoB along with it 4.
- Diet: less saturated fat, more fibre and unsaturated fats.
- Weight and activity: both reduce triglyceride-rich particle production.
- Treating the driver: managing insulin resistance shrinks the small-dense-particle load that inflates apoB.
- Medication: a clinician-set decision, never a self-selected dose.
If you already have an apoB, LDL-C, or full lipid panel in hand, you do not need another test to start making sense of it.
Link · JAMA Cardiology (Sniderman et al., 2019)Apolipoprotein B Particles and Cardiovascular Disease: A Narrative ReviewThe review that lays out why one apoB per particle makes apoB a direct count of atherogenic particles.doi.orgCitations
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295.
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiol. 2022;7(3):250-256.
- Grundy SM, Stone NJ, et al. 2018 AHA/ACC/Multisociety Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188.
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946.
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the EAS Consensus Panel. Eur Heart J. 2017;38(32):2459-2472.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.
Associations to explore with a clinician, not a diagnosis from a single number.
